MIRUM PHARMACEUTICALS, INC.

(MIRM)
  Report
Delayed Nasdaq  -  05/20 04:00:01 pm EDT
25.58 USD   +5.66%
05/18Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
BU
05/10Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
05/05MIRUM PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 553511486812--
Enterprise Value (EV)1 553511330681695632
P/E ratio -5,35x-4,27x-5,76x-5,45x-7,58x140x
Yield ------
Capitalization / Revenue --25,4x11,3x5,08x2,82x
EV / Revenue --17,2x9,44x4,35x2,19x
EV / EBITDA ---1,91x-5,50x-6,81x-7,26x
Price to Book --4,06x6,11x32,7x11,3x
Nbr of stocks (in thousands) 22 56729 25030 48231 746--
Reference price (USD) 24,517,516,024,224,224,2
Announcement Date 03/12/202003/09/202103/09/2022---
1 USD in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 --19,172,1160288
EBITDA1 ---173-124-102-87,0
Operating profit (EBIT)1 -54,7-104-173-149-10114,0
Operating Margin ---906%-206%-63,2%4,85%
Pre-Tax Profit (EBT)1 -52,5-103-84,0-154-10610,2
Net income1 -52,6-103-84,0-154-10910,2
Net margin ---439%-213%-68,1%3,53%
EPS2 -4,58-4,09-2,77-4,44-3,200,17
Dividend per Share ------
Announcement Date 03/12/202003/09/202103/09/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 5,003,1412,915,919,723,5
EBITDA1 -42,7-45,2-32,4-25,0-23,0-44,0
Operating profit (EBIT)1 -42,8-45,6-32,7-36,5-39,0-38,6
Operating Margin -856%-1 452%-254%-229%-198%-165%
Pre-Tax Profit (EBT)1 -47,157,6-36,6-38,2-40,8-40,4
Net income1 -47,157,5-36,6-37,7-40,7-39,8
Net margin -942%1 834%-284%-237%-206%-170%
EPS2 -1,551,91-1,17-1,20-1,30-1,16
Dividend per Share ------
Announcement Date 11/15/202103/09/202205/05/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 ------
Net Cash position1 --157131117180
Leverage (Debt / EBITDA) --0,91x1,06x1,15x2,07x
Free Cash Flow1 -39,6-88,9-133-97,0-39,867,5
ROE (Net Profit / Equities) ---57,5%-195%-220%-104%
Shareholders' equity1 --14678,949,4-9,76
ROA (Net Profit / Asset) ---31,4%-56,8%-51,4%-37,7%
Assets1 --268271212-27,0
Book Value Per Share2 --3,933,960,742,14
Cash Flow per Share ------
Capex1 0,28--0,080,550,10
Capex / Sales ---0,12%0,34%0,04%
Announcement Date 03/12/202003/09/202103/09/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Key data
Capitalization (USD) 812 070 430
Net sales (USD) 19 138 000
Number of employees 144
Sales / Employee (USD) 132 903
Free-Float 95,1%
Free-Float capitalization (USD) 771 983 431
Avg. Exchange 20 sessions (USD) 5 250 469
Average Daily Capital Traded 0,65%
EPS & Dividend